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doi:10.1016/j.ejvs.2010.11.018Abstract Objectives: Pelvic arteriovenous malformations (AVMs) are difficult to treat.
Arterial embolisation is the most common strategy but often has poor results. We report an
alternative surgical approach of controlled intra-operative transvenous embolisation with
long-term results in seven cases.
Materials and methods: Between 1980 and 2008, we treated seven patients (four men, three
women, mean age 50 years). Indications were rectal bleeding (one case), urinary tract prob-
lems (four cases), oedema of lower limb (one case) and high-output cardiac failure (one case).
Four of them had previous operations and three had previous attempts for embolisation. Em-
bolisation of the malformation was performed through the internal iliac vein. This was done
after clamping of all the feeding and draining vessels. The agent used was cyanocrylate
(one case), Ethibloc (one case) and bone wax (five cases).
Results: Mortality was 0%. Complications occurred in two patients (28,5%), one pulmonary em-
bolism and one regressive femoral paresis. Three patients were re-operated for various
reasons. The mean follow-up period was 6 years (1e12 years). Symptoms resolved in all
patients, while control by computed tomography (CT) angioscan revealed one residual shunt.
Conclusion: Complete surgical excision of pelvic AVMs is not always possible. Embolisation
does not offer a permanent cure. Intra-operative transvenous embolisation of persisting
complex AVMs appears to be an alternative approach with good immediate and long-term
results. Ethylene glycol appears to be the most suitable agent.
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Curative Treatment of Pelvic Arteriovenous Malformation 549Pelvic arteriovenous malformations (AVMs) of the anterior
territory of the internal iliac artery (IIA) are rare and most
often congenital. Clinical symptoms related to the AVM
determine the indication for treatment. Proximal ligation of
the IIA or resection has been described but results are poor.1,2
Intra-arterial embolisation can control the symptoms;
however, recurrence is common as any arterial approach will
be too proximal to eliminate the nidus of the AVM due to its
particular anatomic features.3e5 Arterial embolisation has
also been used preoperatively to reduce blood supply, but
with questionable efficacy due to the numerous feeding
vessels of these lesions. Embolisation of the AVM by retro-
grade transvenous approach has been already reported with
successful results in three patients.6,7 We therefore propose,
in complexcases, a controlled intra-operativeembolisationof
the internal iliac vein (IIV) and present our series with long-
term results.
Patients, Material and Methods
We studied retrospectively the data of all patients who
benefited from a treatment of symptomatic pelvic AVM at
Saint-Joseph Hospital in Paris from 1980 to 2008. A written
consent for the procedure was obtained from all the
patients, after a discussion regarding the advantages and
potential risks of the technique.
Patients often had more than one symptom. The presen-
tation in order of frequency was rectal bleeding (one case),
urinary tract problems (three cases), massive oedema of the
right leg (one case) and, finally, high-output cardiac failure
(one case). A high cardiac output was measured in three
patients (9e13 l min1) (Table 1).
Symptomatic patients had a complete physical exami-
nation with additional gynaecological, urological and colo-
noscopic investigation. Other explorations included
a Doppler ultrasound examination with identification of the
dominant arterial pedicles and main venous drainage,
arteriography in the first steps of our experience, more
recently replaced by abdominal and pelvic computed
tomography (CT) angiography with three-dimensional (3D)Table 1 Clinical symptoms and localisation of AVM.
Pt Age, years Sex Clinical symptoms
1 62 F Massive rectal bleeding afte
anal surgery
2 46 F Pelvic pain, iliac mass,
Oedema of lower limb
3 49 M Pelvic pain
Dysuria
Impotence
4 50 M Pelvin pain
Pulsatile rectal mass
Scrotal pulsative vein
5 54 M Pelvin pain
Haematuria
Hemospermia
6 54 F Isolated congestive
heart failure
7 37 M Haematuria
Pulsatile pelvic massreconstruction and transthoracic echocardiography with
cardiac output measurement in three patients.
In the beginning of our experience in the first three
patients,weperformed preoperative arterial embolisation of
the dominant feeding arterial pedicles by the use of rapidly
polymerising agents or coils. The indication was to reduce
bleeding during the operation. However, intra-operatively,
we did not find any significant difference; hence, we decided
not to repeat it in the rest of our patients as it was an addi-
tional procedure with questionable benefit. In seven cases
where complete resectionwas not possible and patientswere
still symptomatic despite previous attempts for treatment,
we had to proceed to transvenous intra-operative embolisa-
tion described later. Follow-up of the patients constituted
clinical examination, Doppler scan and CTangiography in the
immediate postoperative period, 6 months and each 2 years
thereafter.
Technique
The surgery was performed under general anaesthesia. A
median laparatomy was performed to obtain a good expo-
sure aorta, inferior vena cava and iliac vessels. The aorta,
inferior vena cava, common iliac, internal iliac, external
iliac arteries and veins were first carefully controlled. For
women, a hysterectomy and homolateral annexectomy, if
not made before, was required for good exposure of the
internal iliac vessels. Resection of the anterior trunk of the
IIA and its branches was necessary to expose the entire
venous plane. Then, IIV embolisation was performed after
clamping the aorta, common iliac arteries and also the
distal part of the IIV. The embolic agent used was, at the
beginning of the experience, isobutyl cyanocrylate (IBCA)
and Ethibloc, while more recently we are using bone wax of
Horsley. The bone wax is firstly heated in a ‘bain marie’, in
strict asepsy, at 65 C. At this temperature, it has a trans-
parent liquid form with low viscosity and it can be easily
aspirated with sterile syringes. Sterile plastic syringes of
10-cc volume are also placed in warm water to prolong the
period that the wax remains liquid. This gives us nearly 10 sCardiac output, l/mn Site of AVM
r 13 Right broad ligament
Unknown Right broad ligament
Unknown Lesser pelvis, right side
8,5 Lesser pelvis, right side
Unknown Lesser pelvis, right side
9,2 Left broad ligament
Normal Lesser pelvis, right side
Figure 2 Same patient of Fig. 1 after embolisation.
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before it resolidifies in the syringe. Embolisation is then
performed by direct puncture on the centre of the anterior
wall of the IIV and is repeated until complete filling of the
entire venous compartment. As the temperature of bone
wax lowers rapidly to the tissue levels, it regains its solid
state and forms a continuous intravascular cast that fills all
cavities of the AVM and occludes all entries of arterial
feeders. At the end of embolisation and before declamping,
the distal part of the IIV is closed with a continuous suture
of prolene to avoid all risk of proximal migration (Figs. 1
and 2).
Results
Seven patients with complex congenital pelvic AVMs were
treated with this method in our department during the past
30 years. Three of them were women and four were men
with a mean age of 50 years (range, 34e62 years).
The time interval between the beginning of the symp-
toms and treatment in our service was 6.5 years (range
from 3 months to 30 years). Prior to our involvement, in
three patients (patients 1, 2 and 6), there was an unsuc-
cessful surgical attempt for excision. In two patients
(patients 1 and 2), arterial surgery had been also per-
formed. Bilateral ligation of IIA in two cases and aortobiil-
iac bypass with ligation of right IIA and the iliac vein in one
patient were performed. Two patients had previous arterialFigure 1 CT Angioscan of pelvic AVM before embolisation.embolisation sessions in other institutions (patients 1 and 2
at two to four sessions per patient) (Table 2).
In our approach, we did a systematic preoperative
embolisation of the AVM in four patients. For seven complex
AVMs, venous embolisation of ectasic IIV was performed
with cyanocrylate adhesives (one patient), with Ethibloc
(one patient) and bone wax by direct puncture (five
patients). Additional surgical procedures were necessary
for better exposition of the iliac vein (two hysterectomies
with unilateral annexectomy).
The short-term results were excellent. Pain and discom-
fort were relieved immediately, heart failure subsided and
haemorrhage had stopped. Extensive embolisation was
correlated with fever. On postoperative control, for six
patients there were no ultrasound and CT scan signs of
residual AVM, while in one (Patient 1), a unique residual
shunt was observed.
Two complications were observed in the postoperative
period, one severe pulmonary embolism due to migration of
the embolised material (Ethibloc) that was treated medi-
cally and one regressive femoral paresis due to extension of
the embolised material in the posterior branches of the IIV.
In three patients, re-operation was necessary. In one
case of persisting AVM 2 weeks after the first operation,
a larger exposure of the femoroiliac vein permitted a new
embolisation under control of the draining veins. Patient 1
underwent a restoration of colon continuity at 2 months.
Two patients needed excision of the embolised mass, the
first at 4 months for persisting inflammatory syndrome
(cyanacrylate adhesive material) and the second at 12
years for a persisting mass effect on the rectum (Ethibloc
material).
Table 2 Previous surgical procedures (Visceral and Vascular) and embolizations in other institutions.





Ligation of 2 I.I.A. 3 sessions - 7 years





Ligation of right I.I.A.
Ligation of right iliac vein
Pt 5 Ureteral surgery 1 session - 2 months
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The mean follow-up was 71.3 months (12e156 months). On
the last follow-up, all patients were asymptomatic. CT scan
showed one persisting AVM. But three patients were lost
from follow-up after the last visit at 24, 60 and 120 months
(Table 3) (Fig. 3).
Discussion
We report seven cases of pelvic AVM in the anterior terri-
tory of the IIA. Two of them have been previously repor-
ted.8 Congenital pelvic AVM are considered to be focal
remaining, primitive, vascular channels. Extrauterine
lesions seem to have a particular angioarchitecture. This
consists of numerous communications between the anterior
branches of the IIA and venous ectasies draining to the IIV.
The nidus appears in the wall of the vein like AV shunts also
described in the area of lateral dural sinus (vein of Galen
malformations).9 Usually, the shunts develop in the broad
ligament - soft tissues of the lesser pelvis from arterial
branches of one of the IIAs and then drain into the ipsilat-
eral IIV. After embolisation or ligation of the IIA, multiple
feeders may develop from all the pelvic arteries, contro-
lateral IIA, inferior mesenteric artery, middle sacral artery
or branches of iliofemoral artery. The venous drainage may
























7 Ethylene glycolIIV, inferior mesenteric vein or gonadal veins. These
anatomic features explain the high recurrence rate of
arterial therapeutic approaches proving to be too proximal
to eliminate the nidus.
The location of pelvic AVM is usually extra-uterine. In
the female patient, symptoms include vaginal bleeding,
pain and pelvic discomfort. In large AVMs, congestive heart
failure with high flow may ensue.
Uterine AVM is another form of pelvic AVM in the terri-
tory. It may manifest with local symptoms such as meno-
metrorrhagia, local pain or haemorrhage after caesarean
procedure.10,11 In our series, two female patients have had
hysterectomy previously, but lesions turned out not to be
purely uterine (patients 1 and 2).
Pelvic AVM is less frequent in male patients. Presenting
symptoms include pelvic discomfort, rectal pain, genito-
urinary complications such as haematuria and haemo-
spermia, while, in some cases, haematuria after transrectal
prostate biopsy or transuretheral resection of prostate may
occur.12
Preoperative evaluation is now made by non-invasive
imaging studies. Duplex scans may identify the shunt and
measure the flow and identify the dominant arterial pedi-
cles and principal venous drainage. CT scan with recon-
struction is currently the best imaging modality.
Two therapeutic pathways may be considered depending
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Figure 3 Reconstruction of the follow-up CT Angioscan of
patient 1 showing a residual shunt arrising from the medial
sacral artery.
552 A. Mallios et al.ligature or occlusion of the arterial pedicles and the elim-
ination of shunts by excision of the AVM or occlusion of the
zones of shunt.
Reducing the flow in the fistula can be achieved by:
 Proximal arterial ligation that has been attempted in
emergency procedures. It is accepted that it should be
avoided because it leads always to the recruitment of
arterial pedicles from other territories, and reduces the
possibility for future arterial embolisation, if required.
In our series, four patients had previously some arterial
ligation without success in controlling the AVM.
 Selective arterial embolisation, which can be considered
as the first line of treatment of symptomatic AVM. The
most widely used agents currently are cyanocrylate
adhesives such as NBCA (N-Butylcyanoacrylate) or Onyx
(ethylene vinyl alcohol polymer) agent. These tech-
niquesmay be able to control haemorrhage or to stabilise
local and regional complications. However, elimination
of the nidus is often not achieved and radiological signs of
residual shunts are always present.5,13,14 Arterial embo-
lisation of pelvic AVM is a palliative procedure, which can
be repeated when symptoms recur.
Suppression of arteriovenous shunts
 Surgical excision can be attempted in well-localised
lesions as in uterine AVMs11 extra-uterine AVMs into the
broad ligament,8 but it is associated with uncertain
results. For complex cases with persisting symptoms,embolisation of the venous compartment of AVM is an
alternative option. Transvenous approach for treatment
of AV fistula has been reported with success.6 Mituzaki7
published one case of retrograde transvenous occlusion
of pelvic AVM with ethanolamine oleate product.
In seven complex pelvic AVMs, we applied this technique
with success. Agents used for embolisation were, at the
beginning, cyanocrylate agent, Ethibloc and, more recently,
heated bone wax of Horsley. Wax from honeybees is formed
from a mixture of several compounds including esters, free
acids and free alcohol. Bone wax or ethylene glycol is a non-
absorbable haemostatic mixture composed of bee wax (73%),
paraffin (15%) and isopropyl palmitate (12%). Synthetic wax
has not yet replaced natural wax. Traditionally, it is used for
themechanical compression of the bone capillaries. Its safety
has been demonstrated in cardiac surgery when it is used
for haemostasis of the sternum.15 Beewax has amelting point
range of 62e65 C. If heated to nearly 65 C, it becomes
a transparent liquid. We use it at this temperature to inject
into the venous lumen. In few seconds, it solidifies, forming
a continuous intravascular cast, which may fill the matrix
of AVM and eliminate all communications with arterial
feeders. Bone wax elicits a significant foreign body inflam-
matory reaction. The main advantages of this agent are the
extremely quick solid transformation with a very high occlu-
sive seal rate and no degradation in significant quantities.
Further, it has demonstrateda very good long-term safety and
has a very low cost.
We performed intra-operative embolisation of the venous
compartment of pelvic AVM under control of the terminal
part of IIV to avoid any risk of pulmonary embolism. In case 4,
we did not control the iliac vein and patient has developed
severe pulmonary embolism. One complication (patient 2)
was a femoral paresis due to extension of the agent in the
posterior branches of IIV. Due to this, we try now to ligate the
posterior trunk of the IIV, if possible before injection of this
agent. No pelvic discomfort occurred, a complication that
has been observed after massive embolisation of cyanocry-
late or Ethibloc agents.
Embolo-/sclerotherapy is well known to cause soft tissue
and nerve injurywith direct toxicity or by blockage of nearby
microcirculation from diffusion of the embolising agent. This
is inevitable and efforts need to be taken to minimise this
damage. Also important is to balance the benefit of the
patient with the potential complications post embolisation.
Embolo-/sclerotherapy is being used either as single treat-
ment or complementary to surgery; and complications are
nearly 10%.16,17 Although the level of complications we are
reporting appears to be significant, we believe that this
reflects mainly the magnitude of the operation and the
complexity of the cases treated. Furthermore, it should be
taken in to consideration that these patients were given this
option as a last-resort treatment and most of them had
had already previous unsuccessful attempts at surgery or
embolisation.
It is accepted worldwide that treatment of pelvic AVMs
is complicated and requires a multidisciplinary approach
to give a tailored solution for each patient with less likeli-
hood of complications. Endovascular surgery has also been
reported in combination with sclerotherapy with good
results in one patient.18 Although endovascular modalities
Curative Treatment of Pelvic Arteriovenous Malformation 553should be considered when taking decisions to treat these
patients, we feel that due to the complexity of these
lesions a permanent solution by endovascular means would
be rarely feasible.
The following represent some recommendations for the
treatment of pelvic AVMs according to our experience:
 Patients with asymptomatic extra-uterine pelvic AVM
should be followed up by Duplex scan imaging as the
lesion may remain stable.
 Patients with symptomatic AVM with severe pain, high-
output cardiac failure orhaemorrhage should bemanaged
by arterial embolisation, which can be repeated when
symptoms recur. If symptoms improve no further, therapy
is needed because the recurrence is variable. In a few
patients with localised AVM, that resection is considered
feasible, arterial embolisation is also indicated as
apreoperativeprocedurebut it is questionablewhether it
will decrease the risk of intra-operative bleeding.
 Adjunctive procedures should be reserved for patients
with symptoms not improved after embolisation. For
these complex AVMs where surgical extirpation is diffi-
cult or impossible, the alternative of intra-operative
embolisation of the venous compartment under control
of feeding and draining vessels is the best option.
Conclusions
The treatment of pelvic AVMs is challenging and should have
a multidisciplinary character. Selective arterial embolisation
of pelvic AVM is not a radical therapy, irrespective of the
agent used. Embolisation of the venous compartment of an
AVM is an alternative procedure tailored to the particular
angioarchitecture of these shunts. Bone wax seems to have
the most appropriate characteristics. The monitoring of
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